GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Eplerenone tablets (Inspra)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Inspra

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Eplerenone tablets (Inspra) - selected U.S. label sections

Product / population
INSPRA oral tablets. Do not apply hypertension-only exclusions indiscriminately to other labeled indications.
Renal measure
Creatinine clearance in mL/min; indication-specific contraindications.

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal contraindications

For all patients, CrCl at or below 30 mL/min is a contraindication. For treatment of hypertension, additional exclusions include CrCl below 50 mL/min, serum creatinine above 2.0 mg/dL in males or 1.8 mg/dL in females, and type 2 diabetes with microalbuminuria.

Potassium and interactions

Starting potassium above 5.5 mEq/L and strong CYP3A inhibitors are contraindications. Impaired renal function increases hyperkalemia risk; use the full indication-specific potassium monitoring and dose-modification instructions. A smaller dose does not override a contraindication.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Eplerenone tablets (Inspra) - selected U.S. label sections

INSPRA oral tablets. Do not apply hypertension-only exclusions indiscriminately to other labeled indications.

Renal method: Creatinine clearance in mL/min; indication-specific contraindications.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - INSPRA

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Adult eplerenone; selected all-patient contraindications and potassium surveillance. Indication-specific additional restrictions remain applicable.

Renal method: CrCl in mL/min; potassium and serum-creatinine monitoring.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

Eplerenone tablets (Inspra) - selected U.S. label sections

INSPRA oral tablets. Do not apply hypertension-only exclusions indiscriminately to other labeled indications.

Method: Creatinine clearance in mL/min; indication-specific contraindications.

Renal contraindicationsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeEplerenone tablets (Inspra) - selected U.S. label sectionsGlobalRPh RX List - INSPRA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a

Product and population scope

INSPRA oral tablets. Do not apply hypertension-only exclusions indiscriminately to other labeled indications.

RDM32-eplerenone-inspra-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Eplerenone tablets (Inspra) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · INSPRA oral tablets. Do not apply hypertension-only exclusions indiscriminately to other labeled indications.

Renal method: Creatinine clearance in mL/min; indication-specific contraindications.
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal contraindications

For all patients, CrCl at or below 30 mL/min is a contraindication. For treatment of hypertension, additional exclusions include CrCl below 50 mL/min, serum creatinine above 2.0 mg/dL in males or 1.8 mg/dL in females, and type 2 diabetes with microalbuminuria.

RDM32-eplerenone-inspra-1 · Source locator: 4

Potassium and interactions

Starting potassium above 5.5 mEq/L and strong CYP3A inhibitors are contraindications. Impaired renal function increases hyperkalemia risk; use the full indication-specific potassium monitoring and dose-modification instructions. A smaller dose does not override a contraindication.

RDM32-eplerenone-inspra-2 · Source locator: 4; 5.1

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a
Retrieved
2026-09-05
DailyMed Set ID
1a52bedc-8e2c-4116-a296-a87770676b4a
Renal-function method
Creatinine clearance in mL/min; indication-specific contraindications.
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
bd4e13329f58fa7697d78a0a8612f05d12589a083c0def66f3e7943aca040579
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - INSPRA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult eplerenone; selected all-patient contraindications and potassium surveillance. Indication-specific additional restrictions remain applicable.

Renal method: CrCl in mL/min; potassium and serum-creatinine monitoring.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For all patients, the source contraindicates treatment at CrCl 30 mL/min or less, potassium above 5.5 mEq/L at initiation, or with strong CYP3A inhibitors. Check potassium before treatment, within the first week and at one month after initiation or adjustment, then periodically. Additional hypertension-only restrictions must also be reviewed. Hemodialysis does not remove eplerenone. A pharmacokinetic observation is not permission to bypass these contraindications.

RDM43-rxlist-eplerenone-inspra-4123550ad7-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/inspra-drug/
Retrieved
2026-09-07
Renal-function method
CrCl in mL/min; potassium and serum-creatinine monitoring.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4d31151f8851af6e3fb20553df80cfe5593278ad37981f19914c564c5af8e62c

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
5a0a3233b9bff93426c18fa0496db625e0453dbdf51a4295d34033ef72cf605a
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report